October 04, 2007 02:00 ET

Sinclair Pharma plc presents data for pipeline acne product SPHD420

GODALMING, UK--(Marketwire - October 4, 2007) -

Sinclair Pharma plc presents data for pipeline acne product SPHD420
              at World Congress of Dermatology meeting
-data also presented in corrective dermatology, radiation dermatitis,
                    psoriasis, atopic dermatitis-

4 October 2007, Godalming, UK: Sinclair Pharma plc ("Sinclair", SPH:L), the international specialty pharmaceutical company, today presents data at the World Congress of Dermatology, to support its novel pipeline product for acne, SPHD420.

SPHD420 is designed to treat acne in a novel way; it works by breaking down the resilient layer of bacteria that form a 'biofilm' on the skin and then reducing levels of acne-causing bacteria by promoting the activity of beta-defensin, a key element in the body's defence against acne.

To achieve this mode of action, SPHD420 includes delmopinol, which interferes with the ability of bacteria to adhere to each other and to adhere to surfaces, resulting in breakdown of biofilm. An additional complex of ingredients including LMW-HA, is designed to stimulate production of beta-defensin 2 in the skin.

Data presented today shows that human keratinocytes (the type of cell most commonly found in the epidermis of the skin) treated with LMW-HA show increased secretion of beta-defensin 2. Although skin cells were treated for 18 hours, the increase in beta-defensin 2 in the treated cells was seen from 30 minutes.

These data support Sinclair's novel pipeline product for acne. Sinclair plans to file for product registration for SPHD420 in FY09. Preliminary results showing clinical efficacy were presented at the company's R&D day in June 2007, and results from further clinical trials are anticipated in 2008. The market size for acne is currently approximately $2.5 billion, representing nearly a quarter of the dermatology market.

Corrective dermatology

Sinclair also presents data to support SPH911, its pipeline product that is designed to address skin ageing. Data presented today shows that telmesteine, a key ingredient of SPH911, inhibits metalloproteases and hyaluronidase. This is desirable as these substances contribute to the natural breakdown of skin proteins collagen and elastin.

Data presented by Sinclair in June 2007 showed that application of SPH911 resulted in a statistically significant decrease in skin wrinkles, and significantly increased elasticity, hydration and thickness. Target date for filing for registration is FY09. Sinclair expects commercialisation through one or more marketing partners. The anti-ageing market worldwide is estimated at $6.9 billion, with a growing emphasis on products that have scientific proof of efficacy.

Radiation dermatitis

Sinclair presents clinical data today to support Xclair, its on-market product for radiation dermatitis (skin reactions seen during radiotherapy). The interim analysis of a clinical study including 22 patients showed that patients using Xclair had significantly less erythema (reddening) of the skin, burning, and significantly improved quality of life when compared to a control group using a vehicle cream.


Sinclair presented data to support its pipeline psoriasis product SPHD400. Data showed that the key ingredient of SPHPD400 inhibits Human Leucocyte Elastase (HLE) and collagenases, both substances associated with hyperproliferation in keratinocytes. Skin hyperproliferation is a key feature of psoriasis and its reduction is a desirable outcome when treating the condition.

Atopic dermatitis

A poster was presented at the congress to highlight data from a recent multicentre study to evaluate Atopiclair in the management of mild to moderate atopic dermatitis in adults. The study demonstrates that Atopiclair is a safe and effective treatment, delivering significantly superior control of signs and symptoms than patients using a vehicle cream. Patients using Atopiclair were significantly less likely to need rescue medication with a topical steroid during the study period.

Intellectual property

Sinclair has patents or patents pending for its pipeline products and technologies.

- ends -

For further information please contact:

Sinclair Pharma plc                            Tel:  +44 (0) 1483 410 600
Dr Michael Flynn, CEO
Zoe McDougall, Director of Communications

Capital MS&L
Mary Clark, Halina Kukula                      Tel  +44 (0)20 7307 5340

Notes to Editors:

About Sinclair Pharma plc

Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, the UK, Spain and Portugal, and a complementary marketing partner network that spans 82 countries. Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short time frame. The company focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward- looking statements due to a variety of factors.

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information